Continuing Pharmacy Education / CE Master List / Law: Psychedelic Drugs: Can They Make the “Trip” to the Pharmacy Shelf?-RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Law: Psychedelic Drugs: Can They Make the “Trip” to the Pharmacy Shelf?-RECORDED WEBINAR

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's.  This presentation is a Law CE revolving around psychodelic drugs used to treat Mental Health Disorders.

Learning Objectives

1. Review the development of the knowledge of the effects of psychedelic drugs and their potential use in
psychiatry, with an emphasis on psilocybin.
2. Characterize the traditional legal classification of psychedelic drugs and modern reconsideration of their legal
status.
3. Describe efforts at the state level to expand the medical use of psychedelic drugs.

Session Offered

Released:  April 27, 2023
Expires:  April 27, 2026

Course Fee

$17 Pharmacist

ACPE UAN Codes

 0009-0000-23-011-H03-P

Session Code

23RW11-TXJ88

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-22-017-H03-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Gerald Gianutsos, PhD, JD,
Professor Emeritus
University of Connecticut School of Pharmacy
Storrs, CT 

Faculty Disclosure

Dr. Gianutsos has no financial relationships with any ineligible company associated with this presentation.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Download

Post Test Pharmacist

Schwarting Webinar 2023 Post-Test

 

    1. Review the development of the knowledge of the effects of psychedelic drugs and their potential use in psychiatry, with an emphasis on psilocybin.
    2. Characterize the traditional legal classification of psychedelic drugs and modern reconsideration of their legal status.
    3. Describe efforts at the state level to expand the medical use of psychedelic drugs.

 

The tryptamine class of psychedelic drugs (e.g., LSD, psilocybin) produce their psychedelic/therapeutic effects by acting as agonists of a neurotransmitter in the CNS. What is the relevant neurotransmitter system?

 

  1. Serotonin
  2. Dopamine
  3. Glutamate

 

 

The FDA granted “breakthrough therapy” designation to psilocybin for treatment of a specific condition. What condition is it?

  1. Schizophrenia
  2. Treatment resistant depression
  3. Post traumatic stress disorder

 

 

 

Which feature distinguishes a C-I drug from other controlled substances?

  1. High potential for abuse, especially among hi-riskpopulations
  2. Lack of accepted safety for use under medical supervision
  3. No currently accepted medical use in treatment in the United States

 

 

Which state was the first to approve the use of psilocybin for medical use?

  1. California
  2. Oregon
  3. Maryland

 

 

A patient considering psilocybin treatment for a psychiatric disorder asks you for advice; he is specifically interested in disadvantages of this type of therapy. What do you tell him?

  1. Use of psychedelic therapy is time-and resource-intensive
  2. Requires multiple treatments with a slow onset of activity
  3. There is a high risk of autonomic side effects and addiction

 

 

In the state where medical use of psilocybin was first approved, which of the following statements describes its availability?

  1. Psilocybin can be purchased at retail outlets including pharmacies
  2. Psilocybin is available from any therapist throughout the state
  3. Psilocybin is only available in state licensed clinics